ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) Accounts Payable

As of the most recent data (March 2026), LSPRU shows a accounts payable of $10B. That compares with $9.6B in the prior-year period — up 6.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, LSPRU's accounts payable is now $10B (was $9.6B) — a 6.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) is outperforming or lagging.

Tracking LSPRU's accounts payable over time shows whether ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War) is scaling, shrinking, or reshaping that part of the business. The current reading is $10B That compares with $9.6B in the prior-year period — up 6.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has ZyVersa Therapeutics- Units (1 Ord Share Class A & 3/4 War)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $10B) with ownership activity and broader fundamentals.